Melanoma transection doesn't affect overall survival

September 18, 2012
Melanoma transection doesn't affect overall survival
Melanoma transection does not affect disease-free survival or mortality, according to a study published online Sept. 10 in the Journal of the American Academy of Dermatology.

(HealthDay)—Melanoma transection does not affect disease-free survival or mortality, according to a study published online Sept. 10 in the Journal of the American Academy of Dermatology.

Mohsin Mir, M.D., from the Baylor College of Medicine in Houston, and colleagues retrospectively reviewed cases of melanoma at Baylor from 2000 to 2008. Transection rates were determined in 479 cases, and transected tumors were matched with non-transected cases to evaluate survival in a case-control manner.

The researchers found that the rate of melanoma transection was 1.5 percent for excisional biopsies, 4.1 percent for punch biopsies, and 9.0 percent for saucerization biopsies. Mean disease-free survival was 911 days for controls and 832.7 days for the transected group (P = 0.67). Overall survival was not significantly different between the groups (1,073.7 days for control group versus 1,012.4 days for transected group).

"Punch and saucerization biopsies were more likely to transect tumors than excisional biopsies," the authors write. "The transection of did not affect overall disease-free survival or mortality in the population studied."

Explore further: Shave biopsy is a safe and acceptable method for initial evaluation of melanoma

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Women have clear melanoma survival advantage over men

May 1, 2012

(HealthDay) -- Women with localized melanoma have a consistent advantage over men of approximately 30 percent for survival and progression, according to a study published online April 30 in the Journal of Clinical Oncology.

ASCO: Trametinib improves survival in metastatic melanoma

June 5, 2012

(HealthDay) -- For patients with metastatic melanoma with activating mutations in serine-threonine protein kinase B-RAF (BRAF), treatment with the oral selective MEK inhibitor trametinib is associated with improved progression-free ...

Tumor-Infiltrating lymphocyte grade IDs melanoma survival

June 20, 2012

(HealthDay) -- Tumor-infiltrating lymphocyte (TIL) grade is an independent predictor of melanoma-specific survival and sentinel lymph node (SLN) status in patients with localized primary cutaneous melanoma, according to a ...

Researchers study childhood melanoma characteristics

September 7, 2012

Melanoma, newly diagnosed in more than 76,000 Americans in 2011, is the most common and dangerous form of skin cancer. Melanoma is rare in children, accounting for 1 to 4 percent of all melanoma cases and just 3 percent of ...

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

gwrede
not rated yet Sep 19, 2012
And what exactly is "transection"?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.